P/B
3,8
Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
$2.5B
Market Cap • 9/14/2026
2014
(12 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
35,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
6,9
EPS
—
Market Cap
Market Cap
2,5B
EV
1,9B
EV/Revenue
26,3
EV/EBITDA
-4,6
EV/EBIT
-4,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-20,2%
Total Yield
-20,2%
Payout
0%
Retained Earnings
-1,6B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
456,5%
Capex/Revenue
2,4%
Capex/D&A
362,4%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
0,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
93,9%
CAGR Op. Income 5Y
25%
CAGR Net Income 5Y
23,9%
CAGR EPS 5Y
-35,3%
CAGR OCF 5Y
52,3%
Leverage
N.D./EBITDA
1,8
Debt/Equity
0%
Current Ratio
16,9
Quick Ratio
16,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!